Cyclerion Therapeutics, Inc.
CYCN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CYCN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CYCN
Cyclerion Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for mitochondrial disease, currently advancing a Phase 2 study of CY6463 while pursuing a merger to address its limited cash runway and going-concern uncertainty.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for Cyclerion Therapeutics, Inc..
Similar companies
Cyclerion Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for mitochondrial disease, currently advancing a Phase 2 study of CY6463 while pursuing a merger to address its limited cash runway and going-concern uncertainty.
- Cash and equivalents of $1.4M as of 2026-06-30 [sec].
- Zero total revenue and a net loss of $1.8M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $9.1M as of 2026-06-30 [sec].
- Advancing CY6463 in a Phase 2 clinical trial for mitochondrial disease (NCT06402123) [sec_mda · as of 2025-11-12].
- Management has expressed substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2026-05-12].
What works
- CY6463 is in a Phase 2 global study enrolling approximately 44 participants at mitochondrial disease centers of excellence across multiple countries, indicating active clinical development [sec_mda · as of 2025-05-06].
- The company is evaluating strategic alternatives including collaborations, licenses, mergers, and acquisitions to enhance shareholder value [sec_mda · as of 2025-11-12].
What to weigh
- Cash and equivalents of only $1.4M as of 2026-06-30, with no revenue and ongoing net losses, raising substantial doubt about the company's ability to continue as a going concern [sec] [sec_mda · as of 2026-05-12].
- The company expects to need additional funding to sustain operations if the planned merger is not completed, and failure to obtain capital would likely delay development or force cessation of operations [sec_mda · as of 2026-05-12].
- Research and development expenses increased sharply to $730K in Q1 2026 from $36K in Q1 2025, reflecting higher external costs for nonclinical studies [sec_mda · as of 2026-05-12].
From the filings
Quoted directly from source documents.
Substantial doubt about going concern
“Because there is substantial doubt about our ability to continue as a going concern for a reasonable period of time, an investment in our common stock”
SEC MD&A · May 12, 2026
Phase 2 study of CY6463 for mitochondrial disease
“is a global study that will enroll approximately 44 participants at mitochondrial disease centers of excellence in the U.S., Italy, Germany, United Kingdom, Australia, and Canada. ClinicalTrials.gov (NCT06402123)”
SEC MD&A · May 6, 2025
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Management has expressed substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2026-05-12].
- Limited cash runway — Cash of $1.4M as of 2026-06-30 is insufficient to fund operations beyond the near term without additional financing [sec].
- Dependence on merger completion — If the merger is not consummated, the company will need to obtain additional funding to sustain operations [sec_mda · as of 2026-05-12].
- No approved products or revenue — The company has zero total revenue and relies solely on pipeline development and external financing [sec].
What to watch
- Completion of the planned merger, which is critical to the company's near-term liquidity [sec_mda · as of 2026-05-12].
- Progress and enrollment updates for the Phase 2 CY6463 trial in mitochondrial disease (NCT06402123) [sec_mda · as of 2025-11-12].
- Any additional financing or strategic transactions (collaborations, licenses, acquisitions) to extend the cash runway [sec_mda · as of 2026-05-12].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Cyclerion Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cyclerion Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
3.0 months
D/E 0.36 · 0% dilution
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$253K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 84,550 | $130K |
| vanguard capital management llc | 32,274 | $50K |
| citadel advisors llc | 18,261 | $28K |
| blackrock, inc. | 16,797 | $26K |
| vanguard fiduciary trust co | 7,353 | $11K |
| fmr llc | 4,740 | $7K |
| group one trading llc | 192 | $295 |
| osaic holdings, inc. | 130 | $201 |
| activest wealth management | 100 | $155 |
| citigroup inc | 89 | $137 |
Showing top 10 of 14 institutional holders of Cyclerion Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.6%
- Days to cover
- 0.0
- Shares short
- 56,618
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CYCN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cyclerion Therapeutics, Inc.?
Cyclerion Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for mitochondrial disease, currently advancing a Phase 2 study of CY6463 while pursuing a merger to address its limited cash runway and going-concern uncertainty.
What is Cyclerion Therapeutics, Inc.'s lead drug candidate?
Cyclerion Therapeutics, Inc.'s most advanced tracked candidate is cyc-126 (Preclinical) for Treatment-resistant depression (TRD).
Who is the CEO of Cyclerion Therapeutics, Inc.?
Dr. Regina M. Graul Ph.D. is the chief executive officer of Cyclerion Therapeutics, Inc. (CYCN).
Where is Cyclerion Therapeutics, Inc. headquartered?
Cyclerion Therapeutics, Inc. (CYCN) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Cyclerion Therapeutics, Inc. focus on?
Cyclerion Therapeutics, Inc. develops therapies across Neurology, Cardiovascular, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.